Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA, September 9, 2010 - Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research. Ambry Genetics has passed a rigorous certification test plan with precise experimental standards to officially join the Roche NimbleGen Certified Service Provider Program. They will process customer gDNA samples for genomic enrichment, using 2.1 million optimized DNA probes from SeqCap EZ Exome to capture all human coding exons, and sequence the enriched samples using short-read, paired-end sequencing.
"Our Genomics team has processed hundreds of samples for various projects utilizing many target-enrichment technologies. Ambry Genetics is very honored to have been selected by Roche NimbleGen as the first Certified Service Provider in the United States offering the NimbleGen SeqCap EZ Human Exome product. With this addition, we are currently the only service provider in the world to offer the latest in sequence capture technologies to researchers," said Ardy Arianpour, Vice President of Business Development at Ambry Genetics.
"Roche NimbleGen is extremely excited to welcome Ambry Genetics as our first Certified Service Provider in the United States. This addition will provide more researchers with access to the innovative NimbleGen SeqCap EZ Human Exome technology. Ambry Genetics' commitment to high quality genomic and next-generation sequencing services is an ideal fit with our SeqCap EZ Exome technology, and we look forward to this partnership and the innovation and value it will provide to the research market" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures. NIMBLEGEN and SEQCAP are trademarks of Roche. Other brands or product names are trademarks of their respective holders.
Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Contacts
For Ambry Genetics
gwen@gwengordonpr.com